We are a complementary team witch cross-functional skills, particularly in -omics data analysis, molecular biology, clinical data analysis, pneumologists, nephrologists and pathologoists.
Strategic Committee
Strategic Committee
Jean-Michel is an experienced diagnostic company director for 15 years.
He began his career as a sales engineer for 4 years then regional sales manager for 3 years at Bayer Diagnostics acquired by Siemens. He then held the position of Product Manager, then Sales Director for 13 years and 1 year of Germany Business Unit Director for 12 months, at Biomedical Diagnostics (BMD) which became TheraDiag.
From 2006 to 2010, he held the position of Commercial Director and then General Manager at Eurobio from 2006 to 2010 after the takeover of the company (7M€ 40 people 100K EBITDA). His company merged in 2017 with Diaxonhit (Ingen).
To date, Jean-Michel manages an ETI of 184 M€ in 2021 with 180 and which is present in 9 countries with subsidiaries
Strategic Committee
Strategic Committee
After a successful 13-year tenure at Hyperion Solutions, later acquired by Oracle, Jacques began his entrepreneurial journey by founding an IT company: JIS Computing.
In 2010, he co-founded Teo LLS, a logistics leader specializing in bespoke solutions for Biotech and MedTech companies. Teo LLS, known for accelerating clinical trials and ensuring efficient, temperature-controlled movement of pharmaceutical products. During the COVID-19 pandemic, Teo LLS was selected by the French government to manage vaccine distribution logistics, underscoring its vital role in public health.
In 2023, Jacques co-founded Teo Pharma Services, providing state-of-the-art storage for sensitive medical products.
The following year, he launched Ijapaj Ventures, an early-stage VC firm dedicated to developing the life sciences ecosystem. Jacques' commitment to innovation and excellence has made him a transformative force in biotech, MedTech, and pharmaceutical sectors.
Strategic Committee
Strategic Committee
Jean Marie Grumel has dual training in medicine (Faculty of Lyon) and marketing (INSEAD). He worked for more than 40 years in the pharmaceutical industry, first in large groups (Hoechst, Lipha), then in medium-sized companies. which he managed (Jago, Permatec). Its expertise is in Business Development and Drug Delivery.
In 2000, he founded the company IBD3 Pharma Consulting, active in the field of generics (several hundred marketing authorizations obtained in Europe with the assistance of IBD3).
He is co-founder of the Association of BAs Health Angels Rhône Alpes (HARA) which focuses on seed financing of start-ups in the field of Health based in Rhone-Alpes. He became President of HARA in 2019.
He thus had the opportunity to see numerous projects and to confront the difficulties encountered by start-up managers. HARA members invested in Calyseed in 2023; Jean Marie Grumel represents them on the Calyseed Investment Committee. It is in this context that he is a member of the strategic committee of Cgenetix.
Strategic Committee
Strategic Committee
Erik has over two decades of professional experience spanning finance, technology, business development, and venture capital. Starting in the financial services sector in Australia working across the spectrum of finance from banking, insurance, to financial advisory and investment management, he built a strong foundation in financial analysis and business strategy.
He later moved to Europe, where he led commercial strategy and program management initiatives for a London Stock Exchange listed company working across multi-national, multi-disciplinary teams from Estonia, Bulgaria, Ukraine, Israel and the UK.
Currently, as a General Partner at Baltic Sandbox Ventures, Erik invests in early-stage EU-based Deep Tech and Life Sciences with some nexus or economic participation in the Baltic region. His expertise lies in identifying disruptive technologies, guiding startups through strategic decisions from operations to finance and business development, and driving growth.
If you need a LinkedIn link that's here:
External Strategic Advisor
External Strategic Advisor
Allan holds an MBA from Laval University in Quebec and is a graduate of ESIEE in biotechnology.
He is the CEO of VitaDX, a MedTech company working on an in vitro diagnosis medical device dedicated to the early diagnosis of bladder cancer. He has been leading this start-up project since 2013, and brings, as Managing Director, his skills to guide and implement the company's strategic decisions.
He also has experience as a business creator and as a support for innovative start-ups in the field of health. Since the beginning, he has brought his experience and mentorship to the co-founders of CGenetix to help them grow their business.
External Strategic Advisor
External Strategic Advisor
With a degree in General Engineering and a masters in strategy and management from ESSEC Business School, Amine developed a profound expertise in the management of complexes projects and organizations transformation in his career as a senior strategy consultant including for healthcare company.
Amine developed a wide range of skills, throughout his experience: Complexes projects scoping, roadmaps building, transformation plans, operational and financial risk assessment, financial analysis. With his core skills including leadership, agility and adaptability, Amine Mohammadi acts as business advisor to help CGenetix to grow up.
Medical & scientific board
Medical & scientific board
He holds a position at the LUMC in the department of Ophthalmology and genetics as Principal Investigator in the field of uveal melanoma (UM) genetics.
Early on in his career, he contributed to the discovery of Factor V Leiden and making an impact on the community by advancing biomedical sciences has been the goal ever since. The discovery of the CDKN2A founder mutation (p16Leiden) in melanoma families is an example of meaningful research that coincidently earned him a PhD. DNA methylation analysis has been a shared interest for the last 25 years.
With the advent of digital PCR he has developed a digital approach towards methylation analysis that unleashes an endless pool of biomarkers for clinical use. He is directly collaborating with CGenetix scientists to improve in vitro testing capabilities.
Medical & scientific board
Medical & scientific board
Dany Anglicheau is Full Professor of Nephrology at Université de Paris-Cité. He is the head of the Department of Nephrology and Kidney Transplantation of Necker University Hospital, Paris, France and is directing the kidney transplant program.
His research career has developed around the theme of non-invasive biomarker discovery in kidney transplant recipients. He is now a recognized expert in the of biomarkers in kidney transplantation.
Pr. Anglicheau has received several awards including the 2007 Young Investigator Award of the French Society of Nephrology. He was editorial board member of Transplantation for 10 years. He is a member of the French Speaking Society of Transplantation, the French Society of Nephrology-Dialysis-Transplantation and the American Society of Nephrology.
He has published over 210 peer-reviewed articles mainly on kidney transplantation amongst others in various high-impact journal like New Engl J Med, Lancet, Sci Transl Med, Nature Comm, PNAS, J Am Soc Nephrol, Kidney International, Transplantation, Am J Transplant and Kidney Int and Transplant International.
Medical & scientific board
Medical & scientific board
Pierre Galichon is associate professor of Nephrology at Sorbonne University. He is also an attending Physician in Sorbonne University's kidney transplantation department in Pitié-Salpêtrière Hospital, Paris, France. His research lab at the French National Institute for Health and Medical Research (INSERM) focuses on mechanisms of renal repair.
Dr. Galichon received his MD and PhD degrees from Sorbonne University in 2008 and 2013 respectively and worked in the kidney transplantation and renal intensive care unit at Tenon Hospital, France, before moving to Boston for a postdoctoral research project at Harvard Medical School in 2016-2018. In 2018, he was appointed as an associate professor in the renal transplantation department at Sorbonne University.
His research focuses on non-invasive biomarkers of kidney allograft dysfunction, and on the mechanisms of renal repair and resilience after acute kidney injury. He is the principal investigator of preclinical studies on various models of acute kidney injury, and of a government funded study on the prevention of delayed graft function by nicotinamide in kidney transplant recipients.
Medical & scientific board
Medical & scientific board
Marion Rabant is Full Professor of Pathology of Université Paris Cité, specialized in renal pathology.
She is a recognized expert in kidney transplant pathology and involved in the Banff consortium and in several Banff working groups.
Her research focuses on deciphering the mechanism of kidney inflammatory diseases, such as kidney transplant rejection or acute interstitial nephritis using innovative techniques on the renal tissue (multiplex immunofluorescence, spatial transcriptomics, RNA sequencing)
Pr. Rabant has published over 180 peer-reviewed articles mainly in the field of kidney transplantation. She is a member of the Renal Pathology Society and the French Society of Nephrology-Dialysis-Transplantation.
CEO & Co-founder
CEO & Co-founder
Engineer in biotechnology and doctor in molecular biology, Geoffroy Poulet developed a strong knowledge on microfluidic analytical techniques such as NGS & digital droplet based PCR.
Using circulating-cell-free DNA, he implemented new biomarkers dedicated to translational cancer research. With his 4 years’ experience in big diagnostic and pharmaceutical groups, Geoffroy Poulet acquired skills to guide the development strategy of CGenetix.
Driving team element, pro-active with excellent negotiation power, Geoffroy Poulet is also responsible for the establishment of new clinical partnerships.
CSO & Co-founder
CSO & Co-founder
With an Engineer R&D degree in Industrial Biotechnology finished at Newcastle University, Yoan came back to Paris as Research Engineer and achieved a PhD in Immunology and Cancerology at Sorbonne University focusing on digital pathology of lung cancer.
He worked for more than 5 years in collaboration with hospital clinicians in Paris and the AstraZeneca’s Cancer US branch. While leading and managing a research team, he has acquired strong expertise on lung cancer immunology, clinical data and transcriptomic analysis.
His passion in human biology and his wish to make research that benefit the people are the values that drive him to join CGenetix as CSO.
Head of IT & Bio-informatic - Associate
Head of IT & Bio-informatic - Associate
Holder of a bachelor’s in molecular biology and biostatistics, and a master’s in computer science applied to human health from the university Paris-Saclay, Thomas has strong skills in life sciences data analysis.
After a 4 years’ experience in a Finnish company as bioinformatician, where he was responsible for the development of NGS bioinformatic pipelines, web applications and data processing methods, having strongly developed both his technical and project management skills, he joined CGenetix to take the lead of the IT section.
Bio-informatics apprentice
Bio-informatics apprentice
Final year student in bioinformatics at the Université Paris Cité with a strong interest in genetics and genomics. Through her internships at Institut Imagine, Institut Jacques Monod, and Institut Curie, she has developed solid skills in machine learning and data analysis using Python and R.
As an intern, she is grateful for the opportunity to work with this incredible team on challenging projects.
She joined CGenetix in September 2024 as an apprentice in bioinformatics to develop in silico a new generation of biomarkers in transplantation.
Molecular biology apprentice
Molecular biology apprentice
Freshly graduated from a "BUT génie biologique", she is entering the biotechnology engineering program at Sup'Biotech. In order to become more professional, she decided to continue her studies in engineering school with a work-study contract, enabling her to combine theoretical and practical training.
In the future, she would like to become a research engineer in the medical field, to contribute to the evolution of our world.
She joins CGenetix in September 2024 as an apprentice in molecular biology to develop in vitro a new generation of biomarkers in transplantation.
Laboratory technician
Laboratory technician
Pauline Boyer is a senior laboratory technician in CGenetix. After obtaining a Higher National Diploma in Biotechnology, she worked in Germany in a Research Laboratory focused on oncology.
Then, upon arriving in Paris, she joined a medical analysis laboratory in the fields of Biochemistry, Immunohematology, and blood transfusion. Health is essential for everyone, and contributing to this field is her vocation.
She actively participates in the technological development of future diagnostic tests for the company CGenetix and also has the mission of managing the operational aspects of the laboratory.
CGenetix develops the new generation of liquid biopsy biomarkers to evaluate organs damages during a pathological process.